目的 分析頭孢菌素類藥品導(dǎo)致成人凝血功能異常的相關(guān)因素，為臨床預(yù)防和治療不良反應(yīng)（ADR）提供參考。方法 回顧分析2011-2018年黃石市中心醫(yī)院、黃石市普愛醫(yī)院、黃石市中醫(yī)醫(yī)院和黃石市婦幼保健院收集的271例頭孢菌素類藥物致成人凝血功能異?；颊叩呐R床資料、干預(yù)措施及預(yù)后情況，調(diào)查患者性別、年齡、原患疾病、合并基礎(chǔ)疾病、聯(lián)合用藥、頭孢菌素類藥物名稱及累積用藥時(shí)間等相關(guān)因素，數(shù)據(jù)采用采用SPSS 20.0軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果 頭孢菌素類藥物致凝血功能異常例數(shù)占總ADR的例數(shù)的構(gòu)成比呈上升趨勢，從16.06%上升至22.76%；共涉及12種頭孢菌素類藥物，排序前3位的藥物分別為頭孢哌酮舒巴坦、頭孢美唑和頭孢曲松。合并低蛋白血癥、腎功能不全、聯(lián)用影響凝血功能藥物及累積用藥>5 d是頭孢菌素類藥物致成人凝血功能異常的危險(xiǎn)因素。所有患者經(jīng)停藥、對癥干預(yù)等措施后凝血功能恢復(fù)正常，未出現(xiàn)大出血及死亡病例。結(jié)論 對于合并出血危險(xiǎn)因素的患者在使用頭孢菌素類藥物期間應(yīng)嚴(yán)密監(jiān)測凝血功能，及時(shí)發(fā)現(xiàn)凝血功能異常與出血傾向，預(yù)防致死性出血事件發(fā)生。

Objective To investigate relative factors of coagulation abnormalities induced by cephalosporin in adults patients in a hospital, and provide references for clinical prevention and treatment adverse drug reaction (ADR). Methods The clinical data, interventions and prognosis of 271 adults patients with coagulation abnormalities induced by cephalosporin in Huangshi Central Hospital, Huangshi Puai Hospital, Huangshi Traditional Chinese Medicine Hospital, Huangshi Maternal and Child Health Hospital from 2011 to 2018 were retrospectively analyzed. Investigate factors include gender, age, primary disease, underlying disease, combination, cephalosporin name and cumulative medication time. The data were analyzed by SPSS 20.0 software. Results From 2010 to 2018, the composition ratio of coagulation abnormalities induced by cephalosporin in adults patients accounting for the total number of ADR cases was increasing, and the composition ratio increased from 16.06% to 22.76%; A total of 12 cephalosporins were involved, and the top 3 drugs were Cefoperazone/sulbactam, Cefmetazole and Ceftriaxone. Combination of hypoproteinemia, renal insufficiency, combined coagulation drugs and medication>5 d were risk factors for coagulation abnormalities induced by cephalosporin in adults. After withdrawal of drugs and symptomatic intervention, the coagulation function of all patients returned to normal, and no hemorrhage or death occurred. Conclusion For patients with risk factors for coagulation abnormalities should be closely monitored coagulation during the use of cephalosporins. Timely detection of coagulation abnormalities and bleeding tendency should be detected in time to prevent fatal bleeding.